OND Workload Analysis and OODP Restructuring

The Food and Drug Administration (FDA) intends to solicit proposals for the Office of New Drugs (OND) Workload Analysis and Office of Oncology Drug Products (OODP) Restructuring. The objective of this Statement of Work is to obtain a qualified contractor to provide executive level consulting services, program design, development, and implementation services to comprehensively support revamping the workload analysis tool and implementation of process improvements and reorganization for the Office of Oncology Drug Products (OODP). The work is to be performed at the Food and Drug Administration, Center for Drug Evaluation and Research (CDER), at CDER’s White Oak facility located in Silver Spring, Maryland. Scope of Work: The contractor shall provide all required qualified, experienced personnel to carry out the tasks outlined below. The contractor shall work with the Directors of OND and OODP to provide expert assistance in accomplishing the tasks below: 1. Reevaluate, Revamp and Recalibrate OND Workload Analysis Tool 2. Conduct Information Gathering and Analysis 3. Frame Recommendations for Improvement 4. Develop Implementation Plan 5. Train Employees on the New Structure and Roles 6. Roll out changes to the organization 7. Change Management Services and Ongoing Support The anticipated contract type is a labor hour contract for two years, one (1) Base Year and one (1) Option Year. This will be a small business set-aside solicitation. This contract will be awarded on a best value basis. The designated North American Industry Classification System (NAICS) code is 541990. All vendors must be registered in the Central Contractor Registry (CCR) prior to award of a federal contract. The website is http://www.ccr.gov. This announcement is not an RFQ. Interested parties shall submit an email to request the solicitation at [email protected].